TW
REGN icon

TritonPoint Wealth’s Regeneron Pharmaceuticals REGN Stock Holding History

TritonPoint Wealth’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$526K Sell
681
-148
-18% -$113K 0.06% 165
2025
Q4 		$640K Sell
829
-1,938
-70% -$1.32M 0.06% 152
2025
Q3 		$1.56M Buy
2,767
+281
+11% +$159K 0.13% 125
2025
Q2 		$1.3M Sell
2,486
-69
-3% -$38.5K 0.12% 136
2025
Q1 		$1.62M Sell
2,555
-4
-0.2% -$2.75K 0.15% 127
2024
Q4 		$1.82M Sell
2,559
-145
-5% -$122K 0.17% 119
2024
Q3 		$2.82M Buy
2,704
+148
+6% +$165K 0.26% 95
2024
Q2 		$2.69M Buy
2,556
+92
+4% +$89.2K 0.26% 90
2024
Q1 		$1.92M Buy
2,464
+206
+9% +$196K 0.2% 108
2023
Q4 		$1.98M Buy
+2,258
New +$1.86M 0.19% 112

Other funds holding REGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

TritonPoint Wealth's REGN Position: Q1 2026 in Review

TritonPoint Wealth reduced its Regeneron Pharmaceuticals (REGN) stake by 18% in Q1 2026, selling an estimated $113K and leaving 681 shares worth $526K. The position accounts for 0.06% of the portfolio, ranked #165.

TritonPoint Wealth first reported a position in REGN in Q4 2023 and has held it in 10 quarters since. The position peaked at $2.82M in Q3 2024. 1,393 funds tracked by Wall St. Rank hold REGN as of Q1 2026.

  • TritonPoint Wealth held 681 shares of Regeneron Pharmaceuticals worth $526K as of Q1 2026.
  • TritonPoint Wealth sold 148 Regeneron Pharmaceuticals shares in Q1 2026, an estimated $113K.
  • Regeneron Pharmaceuticals made up 0.06% of TritonPoint Wealth's portfolio in Q1 2026, its #165 holding.
  • TritonPoint Wealth first reported a position in Regeneron Pharmaceuticals in Q4 2023 and has held it in 10 quarters since.
  • TritonPoint Wealth's Regeneron Pharmaceuticals position peaked at $2.82M in Q3 2024.
  • 1,393 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.

Based on TritonPoint Wealth's 13F filing for Q1 2026, filed 21 Apr 2026.